Prediction efficiency of serum cystatin C for clinical outcome in patients with cardiac resynchronization therapy

Background Since only 60–70% of select patients with chronic heart failure (CHF) are responders in cardiac resynchronization therapy (CRT), this study aimed to investigate whether serum cystatin C (Cys C) can be used to evaluate the effectiveness of CRT in patients with CHF.